Clinical Trials Logo

TP53 Mutation clinical trials

View clinical trials related to TP53 Mutation.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06413992 Recruiting - Clinical trials for Endometrial Carcinoma

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Start date: May 10, 2024
Phase: Phase 2
Study type: Interventional

This study is an open-label Phase II randomized controlled trial designed to evaluate the safety and efficacy of camrelizumab plus fluzoparib maintenance therapy in patients with recurrent or metastatic TP-53 mutated Endometrial Cancer. The study will also explore the prevalence of homologous recombination reficiency in Chinese patients with TP-53 mutated endometrial cancer and its therapeutic significance.